DYN Dyne Therapeutics, Inc. Common Stock

XNAS 15.20 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

DYN $15.20 —
Key stats
$15.20
Pre-market $15.38 +1.18%
52-Week Range
$12.43 – $27.30
YTD
-17.84%
IV Rank (30D)
0.0
Straddle Price
$1.25
P/C Vol Ratio
13.37
Market Cap
$2.8B
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.29%
Beta vs SPY1.26
Cost of Equity (CAPM)12.21% (VRP-adj)
WACC11.53%
Volatility Risk Premium+170.1pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.5B
Return on Equity (TTM)-74.0%
Book / Price30.8% — banking bias active (P/B is primary)
Debt / Equity0.28
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$22.52 (Market Anchor value)
SMA 20 / Bollinger Mid$17.60
Bollinger Width / SMA20254.4% (drives anchor stability)
Net Debt$-0.5B
Market Cap$2B
Peers used for multiples: ALKS, BIIB, DNTH, EWTX, LLY, NBIX, PTCT, SRRK
60-Day Conviction
53%
20-Day Fair Value
≈ by Nov 3, 2026
$15.25
α +0.4% rank 68%
conviction
29%
40-Day Fair Value
≈ by Dec 2, 2026
$15.60
α +2.6% rank 70%
conviction
73%
60-Day Fair Value
≈ by Dec 31, 2026
$15.43
α +1.5% rank 63%
conviction
53%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 38.9× · 4 peers
Peer EV/EBITDA n/a 0% median 25.7× · 5 peers
Peer P/B $19.73 31% median 4.2× · 7 peers
Peer P/S n/a 0% median 4.8× · 6 peers
Market Anchor (SMA50) $22.52 0% stability 0% (BB-width)
Options Expected (B-L 30d) $15.57 69% 17 strikes · skew +0.48
As of 2026-10-05 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$2.8B

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its P…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan -3.29% 6
Feb -0.46% 6
Mar +1.45% 6
Apr +1.98% 6
May +5.97% 6
Jun +5.59% 6
Jul +15.81% 6
Aug -0.80% 6
Sep -4.84% 6
Oct +7.43% 6
Nov +8.32% 5
Dec -4.55% 5
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $17.60
SMA 50: $22.52
SMA 200: $19.61
Current: $15.20
EMA 12: $16.72
EMA 26: $18.75
MACD: -2.0273 | Signal: 0.0069
BEARISH
ADX (14): 51.64
STRONG TREND
+DI: 8.79
−DI: 40.41

Momentum Oscillators

RSI (14): 20.89
OVERSOLD
Stoch %K: 8.39
Stoch %D: 12.16
Williams %R: -96.75

Volume & Volatility

BB Upper: $21.54
BB Lower: $13.66
NEUTRAL
OBV: -6,290,137
Vol SMA 20: 3,852,528
Vol ROC: -47.52%
ATR: $1.01
True Range: $0.95
HV 20: 72.1%
HV 30: 62.0%
HV 60: 53.7%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-04T00:00:00 – 2026-10-02T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall Assessment: BULLISH (Confidence Level: 8/10)

Key Drivers:

  • Strong technical momentum with a bullish MACD crossover
  • Recent positive news headlines on stock offerings and clinical trial advancements
  • Low volatility regime, indicating potential for further gains

Primary Risks:

  • High beta, indicating increased market sensitivity and potential for larger price movements
  • Negative earnings or regulatory surprises could lead to significant declines

Investment Thesis: Dyne Therapeutics (DYN) presents a compelling investment opportunity due to its strong technical momentum, positive news flow, and relatively low volatility. However, investors should be aware of the high beta and potential for large price swings.

Recent News Sentiment Impact: The recent news headlines have had a predominantly positive impact on the stock's sentiment, with stories on successful public offerings and clinical trial advancements contributing to the bullish tone.

Technical Analysis

Trend Direction:

  • Short-term (1-4 weeks): Bullish
  • Medium-term (1-3 months): Bullish
  • Long-term (3-12 months): Neutral

Support/Resistance Levels: Key price levels include:

  • Lower Bollinger Band ($23.62)
  • Middle Bollinger Band ($25.48)
  • Upper Bollinger Band ($27.34)

Momentum Signals:

  • RSI Interpretation: Neutral (60.96), indicating no strong buying or selling pressure
  • MACD Signal: Bullish, with a crossover above the signal line
  • Bollinger Bands Position: Squeeze, indicating potential for a breakout

Volume Analysis: Institutional interest signals are mixed, with a relatively low volume rate of change (-38.15%) and a moderate OBV (24698332.88).

News & Sentiment Analysis

Recent Headlines Summary:

The recent news headlines have been predominantly positive, focusing on successful public offerings and clinical trial advancements.

Sentiment Assessment: Positive (65%)

Catalyst Identification: Earnings information is not currently available; however, upcoming catalysts include clinical trial results and regulatory approvals.

Market Narrative: The market narrative has shifted in favor of DYN, with positive news headlines contributing to the bullish tone. This aligns with the technical momentum signals, suggesting a potential for further gains.

Risk & Volatility Assessment

Beta Interpretation: High beta (1.92) indicates increased market sensitivity and potential for larger price movements.

Volatility Regime: Current volatility is relatively low (0.77), indicating a potentially stable environment.

Options Market Signals:

  • IV Rank: 18.8% (Low)
  • Current IV: 114.9%
  • Expected Move: $5.20 (32 DTE)
  • Volume Flow: 64 calls vs 25 puts
  • Open Interest: 338 calls vs 40 puts

Market Context & Positioning

Sector Performance: DYN is performing relatively well within the healthcare sector.

Institutional Activity: Mixed signals from institutional interest, with a moderate OBV and low volume rate of change.

Correlation Analysis: R-squared interpretation suggests that DYN moves more independently than the market (0.32).

Relative Valuation: DYN is positioned near its upper Bollinger Band ($27.34), indicating potential for further gains or consolidation.

Key Levels & Action Items

Critical Price Levels:

  • Lower Bollinger Band ($23.62)
  • Middle Bollinger Band ($25.48)
  • Upper Bollinger Band ($27.34)

Breakout/Breakdown Levels:

  • $26.15 (current price)
  • $28.00 (psychological resistance level)

Time-Sensitive Catalysts: Earnings information and clinical trial results are upcoming catalysts.

Risk Management: Stop-loss levels should be set around the lower Bollinger Band ($23.62), with position sizing considerations based on individual risk tolerance.

Generated
Earnings History
9 of 10 under expected move
Avg Expected Move
23.68%
Avg Actual Move
8.14%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-11-12 Pre-Market 13.02% 0.85% 0.07x Within
2025-01-10 Pre-Market 39.37% 32.85% 0.83x Within
2025-02-27 Pre-Market 21.39% 4.50% 0.21x Within
2025-05-08 Pre-Market 23.68% 20.70% 0.87x Within
2025-07-28 After-Close 17.99% 1.18% 0.07x Within
2025-11-05 Pre-Market 18.24% 2.88% 0.16x Within
2026-01-12 Pre-Market 14.08% 2.48% 0.18x Within
2026-03-02 After-Close 64.66% 5.44% 0.08x Within
2026-05-14 After-Close 4.91% 5.61% 1.14x Exceeded
2026-07-27 Pre-Market 19.44% 4.87% 0.25x Within

DYN Options Activity & IV Rank

DYN IV rank history, 52-week IV rank and IV percentile →

IV Rank (30D)
0.0
IV Rank (7D)
0.0
IV (30D ATM)
52.4%
Straddle (30D)
$1.25
Straddle (7D)
$1.25
P/C Volume
13.37
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
2.01
Correlation (SPY)
33.3%
R²
0.11
Ann. Volatility
78.4%
SPY Volatility
13.0%

High volatility - stock moves more than market

Beta & Alpha Over Time

DYN Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 150,185,399 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

254 filers216,481,531 shares$4.71B value144.14% of float
# Filer Shares Value % of Total % of Float Period
1 T. Rowe Price Investment Management, Inc. 30,912,287 $686.56M 14.58% 20.58% 2026-06-30
2 BlackRock, Inc. Custodian 12,404,330 $275.50M 5.85% 8.26% 2026-06-30
3 Jupiter Topco LLC 11,997,738 $266.63M 5.66% 7.99% 2026-06-30
4 FMR LLC Custodian 11,207,000 $248.91M 5.28% 7.46% 2026-06-30
5 Janus Henderson Group plc 13,647,376 $247.43M 5.25% 9.09% 2026-03-31
6 Vanguard Group Inc Custodian 11,215,565 $219.38M 4.66% 7.47% 2025-12-31
7 State Street Corp 7,458,263 $165.65M 3.52% 4.97% 2026-06-30
8 Orbis Allan Gray Ltd 7,006,542 $155.62M 3.30% 4.67% 2026-06-30
9 Atlas Venture Life Science Advisors, LLC 6,800,099 $151.03M 3.21% 4.53% 2026-06-30
10 Vanguard Capital Management LLC 6,310,969 $140.17M 2.98% 4.20% 2026-06-30
11 TCG Crossover Management, LLC 4,615,144 $102.50M 2.18% 3.07% 2026-06-30
12 Vanguard Portfolio Management LLC 4,048,428 $89.92M 1.91% 2.70% 2026-06-30
13 T. Rowe Price Associates, Inc. 3,936,806 $87.44M 1.86% 2.62% 2026-06-30
14 FCPM III SERVICES B.V. 3,848,256 $85.47M 1.81% 2.56% 2026-06-30
15 Geode Capital Management, LLC Custodian 3,743,427 $83.16M 1.77% 2.49% 2026-06-30
16 Vestal Point Capital, LP 3,375,000 $74.96M 1.59% 2.25% 2026-06-30
17 ORBIMED ADVISORS LLC 3,235,684 $71.86M 1.53% 2.15% 2026-06-30
18 Frazier Life Sciences Management, L.P. 3,153,082 $70.03M 1.49% 2.10% 2026-06-30
19 ARMISTICE CAPITAL, LLC 3,087,226 $68.57M 1.46% 2.06% 2026-06-30
20 JPMorgan Chase & Co Custodian 3,151,656 $67.15M 1.43% 2.10% 2026-06-30
21 PERCEPTIVE ADVISORS LLC 2,689,235 $59.73M 1.27% 1.79% 2026-06-30
22 Logos Global Management LP 2,550,000 $56.64M 1.20% 1.70% 2026-06-30
23 Bank of America Corp Custodian 2,233,398 $49.60M 1.05% 1.49% 2026-06-30
24 Venrock Adviser, LLC 2,173,913 $48.28M 1.02% 1.45% 2026-06-30
25 Goldman Sachs Group Inc Custodian 2,157,195 $47.91M 1.02% 1.44% 2026-06-30
4 filers$1.05M notional
# Filer Notional Value % of Total Period
1 Jane Street Group, LLC Custodian $424.21K 40.38% 2026-06-30
2 Susquehanna International Group, LLP Custodian $330.93K 31.50% 2026-06-30
3 Citadel Advisors LLC Custodian $257.64K 24.52% 2026-06-30
4 Simplex Trading, LLC Custodian $37.76K 3.59% 2026-06-30
6 filers$4.43M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $1.39M 31.39% 2026-06-30
2 Jane Street Group, LLC Custodian $1.38M 31.09% 2026-06-30
3 Caption Management, LLC $790.68K 17.85% 2026-06-30
4 Citadel Advisors LLC Custodian $708.50K 16.00% 2026-06-30
5 Simplex Trading, LLC Custodian $144.37K 3.26% 2026-06-30
6 GROUP ONE TRADING LLC Custodian $17.77K 0.40% 2026-06-30

DYN Insider Trading (Form 4)

Latest: 2026-09-08
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-08 Johanna Friedl-Naderer Chief Commercial Officer Sell (S) −1,085 $23.42 -$25.4K EDGAR
2026-09-08 John Cox CEO & President Sell (S) −5,658 $18.88 -$106.8K EDGAR
2026-09-08 Douglas Kerr Chief Medical Officer Sell (S) −5,035 $22.95 -$115.5K EDGAR
2026-08-17 Johanna Friedl-Naderer Chief Commercial Officer Sell (S) −226 $26.28 -$5.9K EDGAR
2026-08-17 Douglas Kerr Chief Medical Officer Sell (S) −1,556 $26.28 -$40.9K EDGAR
2026-08-17 Erick Lucera Chief Financial Officer Sell (S) −1,797 $26.28 -$47.2K EDGAR
2026-08-17 Jason P Rhodes Director Sell (S) −2,586,928 $25.20 -$65.18M EDGAR
2026-08-17 John Cox CEO & President Sell (S) −4,986 $26.28 -$131.0K EDGAR
2026-07-29 Dirk Kersten Director Sell (S) −261,460 $25.51 -$6.67M EDGAR
2026-07-08 Jason P Rhodes Director Sell (S) −777,451 $22.97 -$17.86M EDGAR
2026-06-26 Erick Lucera Chief Financial Officer Sell (S) −2,362 $20.37 -$48.1K EDGAR
2026-06-26 Jason P Rhodes Director Sell (S) −267,760 $21.09 -$5.65M EDGAR
2026-06-24 Dirk Kersten Director Sell (S) −263,962 $20.70 -$5.46M EDGAR
2026-06-23 Barry E Greene Director Grant (A) +57,463 opt — EDGAR
2026-06-22 Dirk Kersten Director Sell (S) −84,355 $20.10 -$1.70M EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

DYN Insider Holdings

11 insiders · @ $15.20
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Dirk Kersten Director 3,586,796 $54.52M -$114.18M 40 2026-07-29
2 Jason P Rhodes Director 1,045,735 $15.90M -$148.46M 20 2026-08-17
3 John Cox CEO & President 375,507 $5.71M $1.39M 15 2026-09-08
4 Oxana Beskrovnaya Chief Scientific Officer 195,840 $2.98M -$3.50M 31 2025-03-13
5 Douglas Kerr Chief Medical Officer 163,854 $2.49M -$325.8K 13 2026-09-08
6 Johanna Friedl-Naderer Chief Commercial Officer 152,897 $2.32M -$60.9K 13 2026-09-08
7 Richard William Scalzo SVP, Head of Finance & Admin. 122,330 $1.86M -$8.71M 35 2025-03-13
8 Erick Lucera Chief Financial Officer 119,766 $1.82M -$228.7K 6 2026-08-17
9 Catherine Stehman-Breen Director 115,713 $1.76M $0 8 2026-06-09
10 Edward Hurwitz Director 91,081 $1.38M $0 7 2026-06-09
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

DYN Proposed Insider Sales (Form 144)

Latest: 2026-09-08
Last 30d: 3 filings · $229K notice value  ·  Last 90d: 20 filings · $92.3M notice value · 8 unique filers · 65% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Atlas Venture Fund XI, LP (4, $51.7M) · Atlas Venture Opportunity Fund II, LP (4, $19.6M) · Atlas Venture Opportunity Fund I, LP (4, $13.7M) · ForDyne B.V. (1, $6.7M) · Cox John (2, $238K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-09-08 Cox John Officer 5,658 $106.8K 2026-09-08 Stifel Nicolaus & Company Inc — EDGAR
2026-09-08 Kerr Douglas Officer 35 $661 2026-09-08 Stifel Nicolaus & Company Inc — EDGAR
2026-09-04 Kerr Douglas Officer 5,000 $121.7K 2026-09-04 Stifel Nicolaus & Company Inc — EDGAR
2026-08-14 Atlas Venture Opportunity Fund I, LP Shareholder 322,465 $8.37M 2026-08-14 Merrill Lynch 10b5-1 EDGAR
2026-08-14 Atlas Venture Fund XI, LP Shareholder 1,359,674 $35.30M 2026-08-14 Merrill Lynch 10b5-1 EDGAR
2026-08-14 Atlas Venture Opportunity Fund II, LP Shareholder 478,377 $12.42M 2026-08-14 Merrill Lynch 10b5-1 EDGAR
2026-08-13 Cox John Officer 4,986 $131.0K 2026-08-13 Stifel Nicolaus & Company Inc — EDGAR
2026-08-13 Lucera Erick Officer 1,797 $47.2K 2026-08-13 Stifel Nicolaus & Company Inc — EDGAR
2026-08-13 Kerr Douglas Officer 2,443 $64.2K 2026-08-13 Stifel Nicolaus & Company Inc — EDGAR
2026-08-13 Atlas Venture Opportunity Fund II, LP Shareholder 94,415 $2.47M 2026-08-13 Merrill Lynch 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio4.2
EV/EBITDA-4.7
TTM Net Income$-0.5B
TTM EPS$-3.3
ROE-74.0%
Debt/Equity0.30